Literature DB >> 1969666

Antianxiety effect of cannabidiol in the elevated plus-maze.

F S Guimarães1, T M Chiaretti, F G Graeff, A W Zuardi.   

Abstract

In order to assess the presence of anxiolytic properties in cannabidiol (CBD) the drug was tested in an elevated plus-maze model of anxiety, in rats. Doses of 2.5, 5.0 and 10.0 mg/kg significantly increased the entry ratio (open/total number of entries), an anxiolytic-like effect. CBD at a dose of 20.0 mg/kg was no longer effective. None of the doses of CBD used changed total number of entries, a measure of total exploratory activity. Diazepam (2.0 mg/kg) also caused an anxiolytic-like effect in this model. These results indicate that CBD causes a selective anxiolytic effect in the elevated plus-maze, within a limited range of doses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969666     DOI: 10.1007/bf02244012

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  6 in total

1.  Comparison of four vehicles for intraperitoneal administration of -tetrahydrocannabinol.

Authors:  R D Sofia; R K Kubena; H Barry
Journal:  J Pharm Pharmacol       Date:  1971-11       Impact factor: 3.765

2.  Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat.

Authors:  S Pellow; P Chopin; S E File; M Briley
Journal:  J Neurosci Methods       Date:  1985-08       Impact factor: 2.390

Review 3.  Cannabinoid pharmacology.

Authors:  W L Dewey
Journal:  Pharmacol Rev       Date:  1986-06       Impact factor: 25.468

4.  Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.

Authors:  A W Zuardi; I Shirakawa; E Finkelfarb; I G Karniol
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

5.  Chronic administration of cannabidiol to healthy volunteers and epileptic patients.

Authors:  J M Cunha; E A Carlini; A E Pereira; O L Ramos; C Pimentel; R Gagliardi; W L Sanvito; N Lander; R Mechoulam
Journal:  Pharmacology       Date:  1980       Impact factor: 2.547

6.  Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat.

Authors:  S Pellow; S E File
Journal:  Pharmacol Biochem Behav       Date:  1986-03       Impact factor: 3.533

  6 in total
  89 in total

Review 1.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

Review 2.  [The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders].

Authors:  U Schneider; J Seifert; M Karst; J Schlimme; K Cimander; K R Müller-Vahl
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

Review 3.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

4.  Effects of cannabidiol plus naltrexone on motivation and ethanol consumption.

Authors:  Adrián Viudez-Martínez; María S García-Gutiérrez; Ana Isabel Fraguas-Sánchez; Ana Isabel Torres-Suárez; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-07-01       Impact factor: 8.739

5.  Cannabidiol in Anxiety and Sleep: A Large Case Series.

Authors:  Scott Shannon; Nicole Lewis; Heather Lee; Shannon Hughes
Journal:  Perm J       Date:  2019

6.  Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats.

Authors:  Erin M Rock; Cheryl L Limebeer; Gavin N Petrie; Lauren A Williams; Raphael Mechoulam; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2017-04-20       Impact factor: 4.530

7.  Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.

Authors:  Jose M Trigo; Dina Lagzdins; Jürgen Rehm; Peter Selby; Islam Gamaleddin; Benedikt Fischer; Allan J Barnes; Marilyn A Huestis; Bernard Le Foll
Journal:  Drug Alcohol Depend       Date:  2016-02-23       Impact factor: 4.492

Review 8.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

9.  Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors.

Authors:  T V Zanelati; C Biojone; F A Moreira; F S Guimarães; Sâmia R L Joca
Journal:  Br J Pharmacol       Date:  2009-12-04       Impact factor: 8.739

10.  Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice.

Authors:  David Cheng; Jac Kee Low; Warren Logge; Brett Garner; Tim Karl
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.